These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 25310192)

  • 21. Effects of donor-recipient combinational CYP3A5 genotypes on tacrolimus dosing in Chinese DDLT adult recipients.
    Liu J; Chen D; Yao B; Guan G; Liu C; Jin X; Wang X; Liu P; Sun Y; Zang Y
    Int Immunopharmacol; 2020 Mar; 80():106188. PubMed ID: 31931373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single-Nucleotide Polymorphism of CYP3A5 Impacts the Exposure to Tacrolimus in Pediatric Renal Transplant Recipients: A Pharmacogenetic Substudy of the TWIST Trial.
    Billing H; Höcker B; Fichtner A; van Damme-Lombaerts R; Friman S; Jaray J; Vondrak K; Sarvary E; Dello Strologo L; Oellerich M; von Ahsen N; Tönshoff B
    Ther Drug Monit; 2017 Feb; 39(1):21-28. PubMed ID: 28030534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
    Elens L; Bouamar R; Hesselink DA; Haufroid V; van der Heiden IP; van Gelder T; van Schaik RH
    Clin Chem; 2011 Nov; 57(11):1574-83. PubMed ID: 21903774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
    Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
    Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of donor
    Wheeler C; Masimirembwa C; Mthembu B; Botha J; Scholefield J; Fabian J
    S Afr Med J; 2024 Apr; 114(3b):e1367. PubMed ID: 39041443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation.
    Díaz-Molina B; Tavira B; Lambert JL; Bernardo MJ; Alvarez V; Coto E
    Transplant Proc; 2012 Nov; 44(9):2635-8. PubMed ID: 23146479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in CYP3A genotypes of a liver transplant recipient and the donor liver graft and adjustment of tacrolimus dose.
    Berger FA; Mulder MB; Ten Bosch-Dijksman W; van Schaik RHN; Coenen S; de Winter BCM
    Br J Clin Pharmacol; 2019 Aug; 85(8):1852-1854. PubMed ID: 31190414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recipient ABCB1, donor and recipient CYP3A5 genotypes influence tacrolimus pharmacokinetics in liver transplant cases.
    Naushad SM; Pavani A; Rupasree Y; Hussain T; Alrokayan SA; Kutala VK
    Pharmacol Rep; 2019 Jun; 71(3):385-392. PubMed ID: 31003147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CYP3A5 and ABCB1 polymorphisms in living donors do not impact clinical outcome after kidney transplantation.
    Yang L; de Winter BC; van Schaik RH; Xie RX; Li Y; Andrews LM; Shuker N; Bahmany S; Koch B; van Gelder T; Hesselink DA
    Pharmacogenomics; 2018 Jul; 19(11):895-903. PubMed ID: 29991328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients.
    Sallustio BC; Noll BD; Hu R; Barratt DT; Tuke J; Coller JK; Russ GR; Somogyi AA
    Br J Clin Pharmacol; 2021 Oct; 87(10):3901-3909. PubMed ID: 33646566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
    Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L
    Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients.
    Pinon M; De Nicolò A; Pizzol A; Antonucci M; D'Avolio A; Serpe L; Dell'Olio D; Catalano S; Tandoi F; Romagnoli R; Canaparo R; Calvo PL
    Sci Rep; 2021 Jan; 11(1):443. PubMed ID: 33432012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation.
    Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
    Pharmacogenet Genomics; 2019 Jan; 29(1):9-17. PubMed ID: 30489455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation.
    Elens L; Capron A; Kerckhove VV; Lerut J; Mourad M; Lison D; Wallemacq P; Haufroid V
    Pharmacogenet Genomics; 2007 Oct; 17(10):873-83. PubMed ID: 17885626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liver Transplant Patient Carriers of Polymorphism Cyp3a5*1 Donors May Need More Doses of Tacrolimus From the First Month After Transplantation.
    Argudo A; González de Aledo JM; Alía P; Ramírez P; Serrano T; Fabregat J; Castellote J
    Transplant Proc; 2015 Oct; 47(8):2388-92. PubMed ID: 26518936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients.
    Genvigir FD; Salgado PC; Felipe CR; Luo EY; Alves C; Cerda A; Tedesco-Silva H; Medina-Pestana JO; Oliveira N; Rodrigues AC; Doi SQ; Hirata MH; Hirata RD
    Pharmacogenet Genomics; 2016 Oct; 26(10):462-72. PubMed ID: 27434656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Donor and recipient P450 gene polymorphisms influence individual pharmacological effects of tacrolimus in Chinese liver transplantation patients.
    Liu J; Ouyang Y; Chen D; Yao B; Lin D; Li Z; Zang Y; Liu H; Fu X
    Int Immunopharmacol; 2018 Apr; 57():18-24. PubMed ID: 29454235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of liver transplant recipient and donor genetic variability on tacrolimus exposure and transplant outcome.
    Coller JK; Ramachandran J; John L; Tuke J; Wigg A; Doogue M
    Br J Clin Pharmacol; 2019 Sep; 85(9):2170-2175. PubMed ID: 31219197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beneficial effects of Wuzhi Capsule on tacrolimus blood concentrations in liver transplant patients with different donor-recipient CYP3A5 genotypes.
    Kou K; Sun X; Li M; Li T; Hu Y; Li S; Lv G
    J Clin Pharm Ther; 2022 Feb; 47(2):200-210. PubMed ID: 34708436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of CYP3A5, CYP2C8, and ABCB1 Polymorphisms With Early Renal Injury in Chinese Liver Transplant Recipients Receiving Tacrolimus.
    Deng R; Liao Y; Li Y; Tang J
    Transplant Proc; 2018 Dec; 50(10):3258-3265. PubMed ID: 30577195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.